Bioqual, Inc. (BIOQ) Stock

About Bioqual, Inc.

Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans numerous critical health domains, including investigations into COVID-19, AIDS, influenza, RSV infection, and various flaviviruses such as Zika and Dengue. Furthermore, their work extends to malaria, hepatitis, and oncology. The firm's comprehensive laboratory capabilities further include processing biological samples, producing virus stocks, precisely quantifying infectious viral loads, and conducting assays like virus neutralization and hemagglutination inhibition. They also utilize advanced techniques such as quantitative PCR, ELISA for antigen and antibody detection, flow cytometry, lymphocyte proliferation studies, and various other cell-based analytical methods. Moreover, Bioqual furnishes specialized support for studies employing animal research models. Established in 1981, Bioqual, Inc. maintains its primary operational base in Rockville, Maryland.

Bioqual, Inc. is headquartered in US.

Bioqual, Inc. (BIOQ) stock trades at $32.50 with a market capitalization of $29.07M. The stock is valued at a price-to-earnings (P/E) ratio of -23.55, price-to-book of 0.83, price-to-sales of 0.69. Over the past 52 weeks the stock has ranged between $32.50 and $43.55, and currently trades 25.4% below its 52-week high.

On profitability, Bioqual, Inc. generates a return on equity (ROE) of -3.46%, return on capital employed of -3.50%, an operating margin of -5.40%, a net profit margin of -2.92%.

Official website: www.bioqual.com